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Attachment 1 
Diabetes mellitus and market analysis 
Diabetes mellitus (DM) is defined as a group of metabolic diseases characterized by 
increased blood glucose levels or hyperglycaemia, essentially caused by a deficient insulin 
action on target tissues. DM typical symptoms include polyuria, polydipsia, weight loss, 
polyphagia and blurred vision. Growth deficiencies and lowered immunization to certain 
infections are also included as DM manifestations, and uncontrolled hyperglycaemia is also 
related to diabetic ketoacidosis or nonketotic hyperosmolar syndrome.(1) Long-term DM is a 
leading cause of serious microvascular and macrovascular complications. Microvascular 
complications are due to small blood vessels damage and include retinopathy (leading to 
blindness), nephropathy (leading to renal failure) and neuropathy (leading to impotence and 
diabetic foot disorders, which may lead to amputation). Macrovascular complications are due 
to larger blood vessels damage and include cardiovascular diseases, such as heart failure, 
strokes and venous insufficiency or peripheral artery disease of the legs.(2) 
DM exhibits two different etiopathogenetic categories: DM type 1, an autoimmune disease 
which represents 5-10% of total diagnosed diabetic population, and DM type 2 or non-insulin-
dependent diabetes mellitus (NIDDM), which represents the remaining 90-95% diabetic 
population.(1) The present work further focuses on NIDDM. 
NIDDM is caused either by a mechanism of insulin resistance or by a relative impairment 
in the insulin secretion process.(3,4) Insulin resistance or defective insulin-stimulated glucose 
transport activity is reported to be caused by an increase in intra-mitochondrial lipid metabolites 
concentration (such as fatty-acyl-CoAs and diacylglycerol), which activate a serine/threonine 
kinase cascade, thus leading to defects in insulin signalling through serine/threonine 
phosphorylation of insulin receptor substrate. As a result, insulin cannot bind correctly to its 
cell-membrane receptor, therefor causing the cell’s incapacity to absorb and process glucose 
and leading to high blood glucose levels. However, plasma glucose signalling remains 
functioning and more insulin is produced and secreted by the pancreatic--cells, further 
contributing to high insulin blood levels and consequently insulin resistance.(5,6) 
Insulin resistance and secretion impairment of this hormone have been linked to a variety 
of factors such as heredity, environmental factors, unhealthy eating habits, sedentary lifestyle 
and stress. Installed worldwide consumerism and urban culture encouraging the prevalence 
of those epidemiologic factors makes NIDDM one of the biggest epidemic diseases of the 
twenty-first century.(7) World Health Organization (WHO) recently published “Global Report 
on Diabetes” estimates that DM prevalence has approximately doubled since 1980, advancing 
in adult population from 4.7% (108 million people) to 8.5% (422 million people) of global 
population in 2014.(8) International Diabetes Federation (IDF) atlas poster summarizes DM 
global numbers and reveals that this silent disease (one in two adults with DM is undiagnosed), 
although not choosing gender (215.2 million men vs. 199.5 million women, in 2015), definitely 
has a greater prevalence in urban areas compared to the rural environment (269.7 million vs. 
145.1 million people, respectively), thus confirming the implication of the epidemiologic factors 
in the incidence and prevalence of the disease. This document also reports that, in 2015, 12% 
of global health expenditure ($673 billion United States Dollars (USD)) was spent on 
diabetes.(9) 
For the pharmaceutical industry, in 2015, health expenditure in DM returned in an estimated 
revenue of $75.1 billion USD, representing approximately 7,9% of global pharmaceutical 
market revenues ($954.1 billion USD).(10–12) The broad diabetes therapeutic market is 
mainly segmented in two different groups: products used in diagnosis and monitoring 
(including syringes and other insulin delivery devices, continuous blood glucose meters, test 
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strips, lancets and glucose meters) and products used in treatment (including insulin and anti-
diabetic drugs). Figure 1 presents the world diabetes market forecast by segment between 
2009 and 2018, highlighting both segmentation by revenue values (in $millions USD) and 
segmentation by total diabetes market percentage.(13) Concerning only the products used in 
diabetes treatment segment, the pharmaceutical industry raised in 2015 an estimated revenue 
of $43-48 billion USD, thus placing antidiabetic drugs in the second place rating of leading 
therapy classes by expenditure and covering approximately 4.8% of the global pharmaceutical 
market revenues.(13–15)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to the IDF “Global Guideline for Type 2 Diabetes” and to the American 
Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) 
“Comprehensive Diabetes Management Algorithm”, NIDDM treatment is primarily focused on 
lifestyle modifications (including diet and physical activity, weight management, foot care and 
sick day management), being pharmacologic treatment required only when glycaemia control 
management (fasting plasma glucose > 100 mg/dL blood, 2-hour post-meal glucose > 140 
mg/dL blood) cannot be achieved by that route. Because diabetes includes one of the several 
heart disease risk factors, management of the disease must involve frequent physiological 
evaluation of not only blood glucose levels (fasting and post-meal) but also of cholesterol, 
triglycerides and blood pressure. Table 1 summarizes the recommended goals for each 
physiological parameter.(16–19) 
 
 
 
 
 
Table 1 – Recommended physiological parameters goals for diabetic patients according to AACE/ACE 
Guidelines(17,18) 
Figure 1 – World diabetes market by segment between 2009 and 2018 (data from 2011, forecast 
from 2012 to 2018): (left graph) diabetes market segments and total diabetes market revenue in 
$million USD, (right graph) diabetes market segments by total diabetes market percentage. (Adapted 
from "Diabetes Management: Products, Technologies, Markets and Opportunities Worldwide 2009-
2018", by MedMarket Diligence, LLC, Report #D510).(13) 
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MEASURES RECOMMENDED GOAL 
Blood Glucose Levels  
Fasting blood glucose 70-130 mg/dL 
Post-meal (2 hour) blood glucose 180 mg/dL 
Haemoglobin A1c (HbA1c) 7.0% 
Cholesterol  
Total cholesterol 200 mg/dL 
LDL-cholesterol 100 mg/dL 
HDL-cholesterol 40 mg/dL for men, 50 mg/dL for women 
Triglycerides 150 mg/dL 
Blood Pressure 130/80 mmHg 
 
According to the diabetes management goals for NIDDM, pharmacological options for blood 
glucose control can be classified into four main lines of action, including in the first two stages 
only oral antidiabetic drugs and progressing for associations of those drugs with different types 
of insulin (see Figure 2).(16–19) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Focusing on the non-insulin segment, the main drug classes prescribed as standard of care 
(SOC) are biguanides (metformin), sulfonylureas (SU) (glipizide, glibenclamide, gliclazide, 
glimepiride) and -glucosidase inhibitors (acarbose, voglibose, miglitol). Add-on therapies 
include incretin-based therapies composed of glucagon-like peptide-1 (GLP-1) analogues or 
receptor agonists, dipeptidyl-peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZD), and 
newest classes including sodium-glucose co-transporter 2 (SGLT2) inhibitors and others (e.g.: 
Figure 2 – Simplified representation of the NIDDM therapeutic management algorithm according to 
IDF and AACE/ACE guidelines 
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bromocriptine).(19,20) Each therapeutic class meets different advantages and disadvantages 
(as displayed on Table 2), which are a result of their diverging line of action and consequent 
effects on the goal physiological parameters (as presented on Table 3). The divergences 
between the existing antidiabetic therapeutic classes justify their use in different stages of the 
disease and its administration choice must be individually aligned with each patient case. 
 
Table 2 – Summarized advantages and disadvantages of antidiabetic drugs by therapeutic class 
ADVANTAGES DISADVANTAGES 
SU  
 Fast onset of action; 
 No changes on blood pressure; 
 No changes on LDL-cholesterol; 
 Convenient dosing; 
 Low cost (generics availability). 
 Weight gain; 
 Increased risk of hypoglycaemia (mainly 
glibenclamide). 
Biguanides  
 Low risk of hypoglycaemia; 
 No weight changes; 
 Decrease on LDL-cholesterol; 
 Decrease on triglycerides; 
 No changes on blood pressure. 
 Increased risk of gastrointestinal side effects 
(nausea, diarrhea); 
 Contraindicated to diabetic patients with 
moderate-severe kidney disease or heart failure; 
 Less convenient dosing.  
-Glucosidase Inhibitors  
 Lower risk of hypoglycaemia (compared to SU); 
 No weight changes; 
 Decrease on triglycerides; 
 No changes on cholesterol. 
 Less effective on HbA1c reduction; 
 Increased risk of gastrointestinal side effects 
(nausea, diarrhea); 
 Inconvenient dosing; 
 High cost (generics not available at the moment). 
GLP-1 Analogues or Receptor Agonists  
 Significant reduction on HbA1c; 
 Favourable effect on weight; 
 Minimal risk of hypoglycaemia. 
 Increased risk of gastrointestinal and injection-site 
side effects; 
 Need for subcutaneous administration; 
 High cost (generics not available at the moment). 
GPP-4 Inhibitors  
 Low risk of hypoglycaemia when combined with 
metformin (compared to SU); 
 Few known side effects; 
 Convenient dosing. 
 Associated with pancreatitis; 
 Less effective on HbA1c reduction; 
 Only valuable as add-on drugs; 
 Less data on potential side effects (recent drugs); 
 High cost (generics not available at the moment). 
SGLT2 Inhibitors  
 High effectiveness on lowering HbA1c and both 
fasting and post-meal glucose; 
 Low risk of hypoglycaemia; 
 Favourable effect on weight; 
 Decrease on triglycerides; 
 Increase on HDL-cholesterol; 
 Lowering effect on blood pressure. 
 Several severe side effects (vulvovaginal 
candidiasis, mycotic infections, osmotic diuresis, 
hyperkalaemia); 
 Dosing must be based on kidney function; 
 Increase on LDL-cholesterol 
 High cost (generics not available at the moment). 
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Table 3 – Antidiabetic therapeutic classes and correspondent drugs summarized description: general line of action, average point reduction in HbA1c (percentage), average point 
change in blood pressure (mmHg), average absolute change in LDL-cholesterol (mg/dL), average absolute change in HDL-cholesterol (mg/dL), average absolute change in 
triglycerides (mg/dL), risk of hypoglycaemia (% of people), and average change in weight (kg). (Adapted from “The Oral Diabetes Drugs: Treating Type 2 Diabetes (Comparing 
Effectiveness, Safety and Price)”, by Consumer Reports Best Buy Drugs, 2009. Copyright 2006-2016 Consumer Reports).(19) 
Therapeutic 
Class 
Drugs 
General line of 
action 
HbA1c 
(mean%) 
Blood 
pressure 
(mean 
mmHg) 
LDL-
cholesterol 
(mean 
mg/dL) 
HDL-
cholesterol 
(mean 
mg/dL) 
Triglycerides 
(mean mg/dL) 
Risk of 
hypoglycaemia 
(% of people) 
Weight 
(mean 
kg) 
Biguanides Metformin 
Inhibits glucose 
production by the 
liver and insulin 
resistance 
0.9-1.4  5-7  15-25 0-7  
SU 
Glimepiride 
insulin secretion 
by the pancreas 
1.3-1.8    10-20 10-22 
2.27-
4.54 
Glipizide 1.3-1.8    10-20 10-15 
2.27-
4.54 
Glyburide/ 
Glibenclamide 
1.3-1.8    10-20 9-14 
2.27-
4.54 
Gliclazide 1.3-1.8    10-20  
2.27-
4.54 
-Glucosidase 
Inhibitors 
Acarbose Delay glucose 
absorption by the 
intestine 
0.6-0.9 IE   10-15 0-5  
Miglitol 0.4-0.9 IE IE IE IE IE IE 
DPP-4 Inhibitors 
Saxagliptine Promote release 
of insulin by the 
pancreas after 
meal 
0.4-0.9 IE IE IE IE IE IE 
Sitagliptine 0.6-0.8 IE    Low  
TZD 
Pioglitazone 
insulin 
resistance 
0.9  8-12 5 35-45 0-3 
2.27-
4.54 
Rosiglitazone 0.9  12-15 3 10-20 4-11 
2.27-
4.54 
SGLT2 Inhibitors Canagliflozin 
glucose 
excretion 
0.9 3.3-5.0 4.5 5 5.3 Low 2-3 
 
Table Symbols and Acronyms: 
 - Variation 
% - Percentage 
 - Decrease 
 - Increase 
IE – Insufficient Evidence (to reach meaningful conclusions) 
 - No meaningful change
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Market analysis reports on type 2 diabetes therapeutics show unanimous growth on the 
use of antidiabetic drugs but variable consumption patterns concerning the different 
therapeutic classes over the last decades (1990’s-2010’s). A 2011 analysis study performed 
on the Moroccan population antidiabetic drugs consumption during 1991-2005 report that 
the Defined Daily Dose (DDD) per thousand inhabitants per day increased from 1.37 to 
4.22, being the largest consumption share in volume held by sulfonylureas (72.22%) 
followed by the biguanides (22.22%). This study also demonstrates a growing consumption 
pattern on biguanides between 2000-2005, concluded to be a result of increased disease 
incidence and diabetic patient number, since metformin is suggested as first line therapy by 
the international guidelines.(21) Similarly, an INFARMED antidiabetics consumption study 
between 2000-2013 reports an overall growth of 94% on the oral antidiabetic drugs use with 
variable consumption pattern by therapeutic class showed in terms of DDD per thousand 
inhabitants per day. Figure 3 illustrates the antidiabetic therapeutic class utilization 
evolution during the studied period, highlighting a consistent increase in biguanides, DDP-
4 inhibitors and recent biguanides-DDP-4 inhibitors association drugs consumption in 
detriment of SU, which utilization pattern shows a decrease between 2003 and 2010 and 
stabilizing since that and the last evaluated year. In 2013, antidiabetic drug combinations 
represent more than 35% of the total antidiabetic drugs consumption versus the 
approximate 30% share for each biguanides and SU.(22) Comprehensiveness of not only 
diabetes increased incidence but also value of convenience in taking one pill embedding 
two different active pharmaceutical principles (APIs) for late-diagnosed patients and for first-
line therapeutic failure cases can here be discussed. 
 
 
 
Considering a broader point of view and assuming United States data as representative 
of the global market  (58% of global antidiabetic market)(23), an American Diabetes 
Association study on the use of antidiabetic drugs in the United States of America between 
2003 and 2012 confirms similar observations, showing an increase in the total number of 
noninsulin antidiabetic drugs prescription by 36.2%. During the analysed period, use of 
biguanides (metformin) increased by 97% and the use of SU remained constant in terms of 
Evolution of antidiabetic drugs utilization in Portugal 
by therapeutic class between 2000-2013 (insulins excluded) 
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Figure 3 – Graphic representation of utilization evolution of antidiabetic drugs in Portugal by therapeutic 
class between 2000-2013 (insulins excluded). (Adapted from “Consumo de antidiabéticos 2000-2013”, 
by C. Furtado and R. Oliveira, 2014, p. 5. Copyright by INFARMED – Autoridade Nacional do 
Medicamento e Produtos de Saúde I.P.)(22) 
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prescription volume, but decreased from 36.3% (2003) to 26.7% (2012) in share among 
noninsulin antidiabetic drug prescriptions (Figure 4). Also, antidiabetic drug combination 
(AD/AD combination) prescriptions revealed an increase between 2007 and 2012, but 
divergently from the Portuguese reality, they represented only 7% of the market share in 
the last year of analysis.(24) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding antidiabetic expenditure by therapeutic class, the same referred INFARMED 
study displays national increased burden since 2008 with DDP-4 inhibitors and biguanides-
DDP-4 inhibitors association market introduction (Figure 5).(22) 
In this scope, availability of low-cost generic drugs versus patent protection of newly 
introduced drugs plays an important role when judging antidiabetic market evolution. 
Comparative analysis of both consumption and expenditure evolution graphs permit the 
following conclusions:  
 Decreased consumption of SU did not translate in proportional decrease in the 
correspondent expenditure, suggesting stabilization between branded and generic 
marketed sulfonylureas during the analysed period; 
 Marked increase in consumption of biguanides was not proportional to the increase 
in the correspondent expenditure, suggesting merging of generic drugs during the 
analysed period; 
 Variable consumption patterns of the antidiabetic market are driven by cost-
effectiveness relationship and thus are mainly due to the balance between 
introduction of new therapeutic options and merging of generic drugs, which translate 
the evolution of intellectual development and interpretation of the disease. 
 
 
Number of antidiabetic drugs prescriptions by therapeutic class 
in the US between 2003-2012 
Figure 4 – Graphic representation of antidiabetic drugs prescription by therapeutic class in the 
US between 2003-2012. (Adapted from “Use of Antidiabetic Drugs in the U.S., 2003-2012”, 
by C. Hampp et al., 2014, Diabetes Care, 37(5), p. 1367-1374. Copyright American Diabetes 
Association)(24) 
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In this context, NIDDM therapeutic area has been stated as a “crowded market”, 
displaying many branded and generic options, with a sustainable growth expected ahead, 
referring the 2014 reviewed diabetes pipeline to 198 new medicines to treat either type 1 
and type 2 DM, counting 146 drugs with direct application in DM (30 for type 1 DM, 100 for 
NIDDM and 16 for unspecified diabetes) and 52 drugs for diabetes-related conditions.(25) 
Suffice it to say that current therapeutic options are considered insufficient therapies since 
considerably high unmet needs continue to exist, mainly concerning patient awareness and 
compliance, diagnosis rate, and sustainable efficacy and safety of drugs.(23,26) Despite 
the well-populated pipeline, several studies reveal that during the next ten years none of 
the drugs slated to reach the market will significantly diminish the level of unmet needs and 
new therapeutic classes are not likely to emerge. In order to offset the impact of 
approaching patent expiries of blockbuster antidiabetic drugs, pharmaceutical companies 
are prioritizing competitive pricing rather than therapeutic value, returning in the observed 
saturation of the late-stage pipeline with “me-too” drugs (i.e. drugs that exhibit minor 
differences compared to those already in the market) and new combinations of existing 
therapies.(26–30)  
However, due to the increasing prevalence and progressive nature of the disease, 
changes in the current NIDDM therapeutic universe are paramount. In the present scenario 
where the consumption of add-on therapies is overlapping the SOC segment, with a DDP-
4 inhibitor drug (sitagliptin, Januvia) dominating the non-insulin market, guidelines 
changes concerning the therapeutic class application are expected for the foreseeable 
future. A Frost & Sullivan’s recent analysis forecasts that DDP-4 inhibitor drugs will continue 
to dominate the non-insulin market both as single therapy and as fixed-dose combinations 
with metformin, and that the new SGLT2 class will overtake the GLP-1 class for the number 
two spot among add-on therapies. As for the said “old therapeutic classes” – biguanides 
and SU – two options are in stake: change and adapt or eventually fall into disuse (like 
TZD). For the current first-line therapy metformin, its cost-effectiveness-safety relationship 
Figure 5 – Graphic representation of Portuguese National Health Service expenditure on antidiabetic 
drugs by therapeutic class between 2000-2013 (insulins excluded). (Adapted from “Consumo de 
antidiabéticos 2000-2013”, by C. Furtado and R. Oliveira, 2014, p. 5. Copyright by INFARMED – 
Autoridade Nacional do Medicamento e Produtos de Saúde I.P.)(22) 
Evolution of Portuguese National Health Service expenditures on antidiabetic drugs by 
therapeutic class between 2000-2013 (insulins excluded)  
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profile reinforced with new improved formulations already in pipeline phase II (by Elcelyx 
Therapeutics™), odds tend to confirm its continuity as prime therapy. Concerning SU, 
statistics speculate a long-term fall into disuse in the NIDDM therapeutic landscape.(20) 
This work focus on the application of new synthetic and crystal engineering approaches 
made over two drugs of the SU therapeutic class of compounds, seeking their reassurance 
as valid NIDDM therapeutic options with capacity to adapt to the presented market 
demands. 
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Annex 2 
Glibenclamide and gliclazide pharmacodynamics and 
pharmacokinetics 
GBL is rapidly absorbed from the gastrointestinal tract, reaching onset of action and 
maximum plasma concentration (Cmax), respectively, within 1 hour and 2-4 hours after oral 
administration. It’s absorption rate from stomach, duodenum and colon is practically the 
same and retention time is greater in the colon. This drug is primarily metabolized in the 
liver, originating two metabolites through cytochrome P450 glycosylation: 4-trans-
hydroxyglyburide and 3-cis-hydroxyglyburide. These weakly active metabolites do not 
contribute with clinical significance to GBL hypoglycemic action in humans, being equally 
excreted through bile and urine (50% by each route), with a clearance of 78 mL/h/Kg. 
Differently from other sulfonylureas, GBL is characterized for being primarily excreted via 
urinary tract, fact responsible for marked variations on the clearance parameter of 
individuals with renal impairment.(31,32) For that, although 4-trans-hydroxyglyburide is 
reported as a non-active metabolite, its retention in the kidneys determine extended 
hypoglycemic effect (~24h), which can be severe with patients with chronic kidney 
disease.(33,34) Described as a weak acid, GBL unchanged drug is ~99% nonionically 
bound to serum proteins, the same occurring to its 4-trans-hydroxy derivative (~97%).(35) 
This high plasma protein binding rate associated to its poor water-solubility lead GBL to 
determine increased pharmacokinetics and pharmacodynamics variability and 
bioavailability problems.(36) Consequently, GBL demonstrates a higher hypoglycemic risk 
profile when compared to other sulfonylureas (~2%), but it is also considered twice as potent 
as the second-generation agent glipizide.(37) Besides its inadequacy for diabetes treatment 
in urinary tract impairment patients, for those with associated cardiovascular pathology GBL 
is considered safer than all other oral anti-diabetic medication, reporting less mortality and 
morbidity hospital events. In this scope, it has also been proved that GBL decreases the 
need for photocoagulation and demonstrates a protective effect on the combined 
microvascular outcomes of retinopathy and nephropathy, two very common diabetes 
mellitus complications.(37)  
 
Comparatively to GBL, GCZ reaches maximum plasma concentrations approximately 
four-times higher in one-third of the time past oral administration(38), it also has wider inter-
and intra-individual variability.(39) Also, divergently from GBL, GCZ mechanism of action is 
specific for pancreatic SUR1 receptors (being described as the most selective SU), thus 
hypoglycaemic adverse events are less common and GCZ are considered safer than GBL. 
As for GBL, GCZ is also absorbed along gastrointestinal tract, mainly in jejunum (55.9%) 
and ileum (20.7%), but with a one hundred-times greater mean absorption rate and 
approximately two-times greater mean retention time. PPB is also marked for this SU, but 
sufficiently lower to impact a greater distribution volume and, in some cases, a greater half-
life. GCZ excretion is mainly processed via renal route (60-70%) with a clearance of 
0.78L.h-1, which in turn is considerably lower than GBL’s. Although with similar 
pharmacological efficacy, as a results of its safer profile, GCZ is much more prescribed than 
GBL.(40) Table 4 resumes GBL and GCZ’s pharmacokinetic parameters. 
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Table 4 – GBL  and GCZ pharmacokinetic parameters: Absorption, Distribution, Metabolism and Excretion 
API 
ABSORPTION DRISTIBUTION METABOLISM EXCRETION 
Local 
tmax 
(h) 
Cmax 
(g/mL) 
PPB 
Vd 
(L) 
t1/2 
(h) 
Local Type Type 
CL 
(L.h-1) 
ke 
(h-1) 
Glibenclamide 
Stomach 
(AR=0.4770.133g.h.mL-1; 
RT=2.670.35h) 
Duodenum 
(AR=0.4750.142 g.h.mL-1; 
RT=2.420.48h) 
Colon 
(AR=0.4860.301g.h.mL-1; 
RT=3.550.68h)(41)1 
3.03 
0.23(42)2 
0.273 
 
0.0258(42)† 
99% 
(97% major 
metabolite)(43) 
9-
10(44) 
10(44) Liver 
Hydroxylation 
by 
CYP3A4(45) 
Renal 
(50%) 
Biliary 
(50%)(43) 
3.1(46)3 0.07(46)‡ 
Gliclazide 
Duodenum (14%) 
Jejunum (55.9%) 
Ileum (20.7%) 
Colon (9.4%)(47)4 
MAR=32.8710.32g.h.mL-
1; MRT=6.931.87h(38)5 
1.64 
0.49(38)** 
4.20 
1.33(38)** 
94%(39) 
13-
24(39) 
8.1-
20.5(39) 
Liver 
Hydroxylation 
by 
CYP2C9(39) 
Renal 
(60-70%) 
Biliary 
(10-
20%)(48) 
0.78(39) 
0.20 
0.006(38)** 
 
Table Acronyms and Abbreviations: 
AR – Absorption Rate; MAR – Mean Absorption Rate; RT – Retention Time; MRT – Mean Retention Time; Cmax – Maximum/Peak Plasma Concentration; tmax – Time (past administration) at which Cmax 
is observed; PPB – Plasma Protein Binding rate; Vd – Distribution Volume; t1/2 – Plasma Half-life Time; CL – Clearance (volume of blood cleared of drug per unit time); ke – Elimination Constant
                                               
1 Randomized crossover study with eight healthy volunteers and six diabetic patients: dosage instilled once into the stomach and once into the duodenum. 
2 Randomized crossover study with twenty-four healthy subjects: administration of 10mg of GBL (two tablets of Daonil 5mg) 
3 Non-obese patients group (n=8): maximum dosage of 20mg per day, 12 weeks of tratment. 
4 In-vivo observed data after oral administration of 80 mg of GCZ (immediate release tablets). 
5 In-vivo observed data after oral administration of modified release minitablets in rats. 
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